Phase II Clinical Study of Camrelizumab Combined With Chemotherapy or Anlotinib in Advanced Esophageal Squamous Cell Cancer
Clinical trial NCT05322499 · UNKNOWN
Trial details
- NCT number
- NCT05322499
- Sponsor
- Zhejiang Cancer Hospital
- Status
- UNKNOWN
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2022-04-15
- Primary completion
- 2023-04-15
- Enrollment
- 80
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.